Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / BONUS CONTENT: Dr. Jennifer Plichta, Duke University, Part 1
Transcript
- 0:00You attend the dinners and luncheons, maybe a pop up shop.
- 0:03You sign the pink car and participate in a tennis event or
- 0:07a special run or walk. So what does earlier.org do with
- 0:11all of your donations? In today's Part 1 of a special
- 0:14two-part series of Isn't That Interesting, Martha Kaley,
- 0:17Founder and Executive directorofearlier.org, speaks to
- 0:21a Duke oncologist who is putting your dollars under the
- 0:25microscope. This is Doctor Jennifer Licta,
- 0:29and I was so happy to have her join us.
- 0:32And she's just going to talk about her research, the
- 0:36grantsthatearlier.org funded, where they stand, what brought
- 0:41her into that work, and so she's just going to share some of her
- 0:44information. So just stay tuned and here she
- 0:47is. Hello, thank you so much for
- 0:49having me today and for the opportunity to share some of the
- 0:52research that we're doing in our lab.
- 0:53And thank you to earlier for the funding for these research
- 0:57projects for without the funding, we certainly couldn't
- 0:59have done this work. And we are so grateful for the
- 1:02opportunity to collaborate together so that we continue to
- 1:04move forward and hopefully make movement and ending breast
- 1:08cancer. So just have some information
- 1:10I'd like to share with you today.
- 1:11Perfect. Should be good to go here.
- 1:13So, so again, this is a progress report for some funding that
- 1:16I've received for my lab related to two different projects
- 1:19actually. So just this back a little bit
- 1:22of background about me first though, I'm a breast surgical
- 1:24oncologist. I did my general surgery
- 1:26training at Loyola, my fellowship in Boston, and I've
- 1:29been an attending surgeon at Duke since 2016.
- 1:33I serve in multiple other roles including I'm the program
- 1:36director for our fellowships, a part of the training program,
- 1:38and then I run what's called basically our high risk breast
- 1:41clinic and our clinical cancer genetics program.
- 1:44And then I have appointments both in surgery and in
- 1:46population Health Sciences. I also serve on multiple
- 1:49national committees through National Consortium of Breast
- 1:52Centers, for which I'm the current president.
- 1:54I chair a few different committees and other
- 1:56organizations and vice chair and others just as back way to tell
- 2:00you I do a lot of things other than research, but certainly way
- 2:03they all go together, at least in my mind.
- 2:07So the BAM lab as I call it, which stands for breast and
- 2:10more, it really has two main areas of focus. 1 is in
- 2:13developing prognostic staging systems, which is really a fancy
- 2:17way of say, helping determine what survival looks like after
- 2:20breast cancer, meaning how long really that quantity of life
- 2:23after a breast cancer diagnosis. And then the other area is in
- 2:27breast cancer risk, which is largely where this funding has
- 2:29been tied to, is this breast cancer risk space.
- 2:32And when I'm talking about breast cancer risk, it's really
- 2:34related to 4 main risk factors and those, not that there aren't
- 2:37others, but the ones that I mostly look at are people who
- 2:40have genetic mutations related to breast cancer, those who've
- 2:43had atypical or abnormal breast biopsies, people with a family
- 2:47history of breast cancer, and those who've had radiation to
- 2:50the chest wall. All of those things are known to
- 2:52be pretty dramatic risk factors for breast cancer.
- 2:55And then I, you know, clinically, I see patients
- 2:57trying to help assess that risk and then how do we manage that
- 3:00risk? So just this isn't what's
- 3:02related to the funding here, but it is a large part of what we do
- 3:05in my lab. So I wanted to just, you know,
- 3:07give a little background on what that looks like developing these
- 3:09prognostic staging systems, which again is survival.
- 3:13How long is survival after a breast cancer diagnosis?
- 3:16So one of the main things we've looked at first is really
- 3:19metastatic breast cancer. So people who have what we call
- 3:22metastatic or stage 4, or where the breast cancer has spread
- 3:26outside of the breast and it's gone to other parts of the body,
- 3:29such as the bone, the brain, those types of things, right now
- 3:32when you have that diagnosis, it's all goes into one bucket.
- 3:35So you can see my pink bucket here.
- 3:37If you've got metastatic or stage 4 breast cancer, it's all
- 3:40considered basically one big group in terms of survival.
- 3:44OK, I know there's lots of other ways, but in terms of survival,
- 3:47they get one category. And my question really has
- 3:50always been, is that right? Is that really how we think of
- 3:53stage 4? Because in my mind, they're not
- 3:55all the same. And so really what we've done is
- 3:58we've taken that one bucket of stage 4 and we've divided it up
- 4:01into four categories, which I've been calling ABC and D.
- 4:06So not just stage 4 breast cancer, but stage 4A or 4B or 4C
- 4:11or 4D. And that's based on again, what
- 4:13those survival outcomes look like.
- 4:15Meaning the longer you live after a diagnosis, you get out
- 4:18an A and the, you know, the shorter the survival, you might
- 4:22be down in category C or D. And the work that we've done has
- 4:25shown that we can do that. So again, we can take you from
- 4:28being all one group of patients, all stage 4 together, and this
- 4:31is what survival looks like, to taking you into 4 categories.
- 4:35And you can see that we have 4 different curves, meaning that
- 4:38some people do indeed do better, meaning they live longer than
- 4:43other people with stage 4. So they're really not all the
- 4:46same. So we can't just call everybody
- 4:48stage 4 and it means the same thing.
- 4:50Some people with stage 4 breast cancer, unfortunately, are
- 4:54probably not going to live more than a couple years and others,
- 4:56as you can see here, they may live 5 or 10 years after this
- 4:59diagnosis. And so it really doesn't make
- 5:02sense to kind of lump them all together anymore.
- 5:04We really need to be thinking about them separately.
- 5:07And then one of the reasons, just one last note on this topic
- 5:10that this is important is because in other stages of
- 5:13breast cancer, stage 1-2 and three, we think we can cure
- 5:18those people. So if you come in with that,
- 5:20what we call early stage breast cancer, we treat you with what
- 5:23we call curative intent, meaning our goal is to get rid of all
- 5:26known cancer in the body. Whereas when somebody has stage
- 5:294 disease, we think of that as something we can't cure anymore.
- 5:33You're probably going to end up dying from or at least with your
- 5:36breast cancer. And So what we decided to look
- 5:39at is because some people with stage 4 live so long and do so
- 5:42well, maybe they do better or just as well as some people with
- 5:46other types of earlier stage breast cancer.
- 5:49And that's what you can see here.
- 5:51So just kind of showing you these pictures.
- 5:53The blue lines represent what we call stage 3 breast cancer,
- 5:56which remember I said stage 3 is something we think we can cure.
- 6:00And the red lines represent the stage 4 again, something we
- 6:04don't think we can cure. But based on where those lines
- 6:07go, you can see that some of those red lines are right next
- 6:10to the blue lines, meaning that some people with stage 4 breast
- 6:14cancer do just as well as stage 3.
- 6:16Yet when I'm, when I'm talking to these patients, I'm telling
- 6:19one, I can cure you and the another, Nope, I can't do
- 6:22anything for you, just treat you and keep you comfortable or
- 6:25palliate. But maybe that's not the right
- 6:28mindset. And so where we're going from
- 6:30here is really trying to think about how we approach these
- 6:33patients. Are we able to maybe cure more
- 6:35people than we thought? Is that really what our goal
- 6:38should be? So again, this wasn't really the
- 6:40focus of the grant funding we got from earlier, but wanted to
- 6:43let you know this is part of the work that we do.
- 6:45So now I'd like to shift gears and spend the rest of the time
- 6:48talking about the funding that we've been so fortunate to get
- 6:51from earlier.org and just explain to you the 2 main
- 6:54research projects that we've been able to focus on because of
- 6:57the funding and the support that we've gotten from earlier.
- 7:00So the first project that we had funded was really looking at the
- 7:04relationship between atypical breast lesions or abnormalities
- 7:10in the breast. We call them atypia, but they're
- 7:12basically just think of them as abnormal and looking at that
- 7:15genetic relationship between that atypia and a breast cancer
- 7:18diagnosis. So what I'm showing you here is
- 7:21think of these as the milk duct. And you can see there's a whole
- 7:25spectrum of things going on here.
- 7:26And we're going to come back to that in just a moment.
- 7:29But just as a refresher, let's remind ourselves of what the
- 7:32breast is made of. So the breast basically sits on
- 7:35the chest wall on top of the chest muscles, and it's mostly
- 7:39made-up of fatty tissue. And on the right hand side, that
- 7:41yellow stuff is all the fat. And then within all that yellow
- 7:45stuff, you see the looks kind of like a tree growing in the
- 7:48breast. And those are the milk ducks,
- 7:50which are those little tube or string like things.
- 7:53And then the lobules look like the ends of a tree.
- 7:55And those are those like puffy looking pink things.
- 7:58But those milk ducts, as you can see here, they look like little
- 8:01tubes or little strings, or we can think of them like a pipe.
- 8:05And so if you take a pipe like just think like a drain pipe or
- 8:08something and you cut it on end, that's what we're going to take
- 8:11those milk ducts. And that's what we're looking at
- 8:12here. So going back to this picture
- 8:14again, on the far left side, that's a normal milk duct or a
- 8:17pipe that carries breast milk. And if you cut it on end, you
- 8:20can see those cute little cells all look totally the same and
- 8:23nice and neat and organized. And as it doesn't really matter
- 8:27the exact specifics. But as we go from left to right,
- 8:30you can see we've gotten some of those red cells, which are the
- 8:32abnormal cells or the atypical cells.
- 8:35And the further to the right you go, the more abnormal they get
- 8:38and the more of them there are. And that progression has
- 8:41different names. So we go from normal to in the
- 8:44middle, the atypia that the focus of this project.
- 8:46And on the far right side, we have an actual invasive breast
- 8:49cancer. But you can see they they
- 8:51probably look a little bit similar.
- 8:53There's just some very subtle differences between the two,
- 8:56often having to do with how much of it there is.
- 8:58And So what our question was is really focusing on this atypia
- 9:01and this invasive breast cancer. Are there similarities between
- 9:05the two? So when you have these abnormal
- 9:07findings in the breast, does that mean something about your
- 9:10risk of getting breast cancer down the road?
- 9:13And so that's where this study comes into play.
- 9:15So one of my collaborators, Dr. Marks, who's really been helping
- 9:19champion this work, has actually done the same study looking at
- 9:23not atypia, but something called DCIS.
- 9:25So going back to this slide, see that thing in the middle between
- 9:28the two pink arrows that DCIS, that's that precancer or pre
- 9:32invasive cancer that some people call it.
- 9:35So his study was looking at that DCIS and invasive cancer.
- 9:38And what he showed is that there is about 80% of cancers that are
- 9:42related to that prior DCIS. So because of that relatedness,
- 9:46meaning they look similar, the genetic findings we see in DCIS
- 9:50are similar to what we see in invasive cancer.
- 9:53We thought, well, maybe that does extend down to atypia.
- 9:56So that was really the question that we sought to ask.
- 9:59And this is where that funding from earlier came in handy.
- 10:01So we wanted to know, are these atypias, which are that step
- 10:05right before DCIS, are they also genetically related to
- 10:08subsequent breast cancers? So we actually found some cases
- 10:12at Duke where a patient had both atypia and then later developed
- 10:15invasive breast cancer in the same breast.
- 10:18And we had a pathologist on the team who was able to identify
- 10:21these two areas. And we took those tissue samples
- 10:24out of the out of the specimens and we did genetic testing on
- 10:29them, which was actually through something called whole genome
- 10:31sequencing and looked at copy number variation.
- 10:33Those technicalities are not important.
- 10:35So let's just call it we did some genetic analysis on these
- 10:38two areas, on the atypia and on the invasive cancer.
- 10:43So we were able to find 12 cases or patients that had had those
- 10:46two diagnosis. Again, atypia and invasive
- 10:49cancer. Average age was just about 60
- 10:51years old and the time period between the atypia and the
- 10:55breast cancer was about five years and those cancers were
- 10:58pretty close to the breast atypia.
- 11:01And nine of those 12 and 10 of them were hormone sensitive.
- 11:05Only one of them is what we call triple negative, which is not
- 11:08particularly important. But just to say that we usually
- 11:10see that in the atypia, that often times the cancers women
- 11:13get with atypia are hormonally driven or hormone sensitive.
- 11:18So how did we do this? So I told you we got some
- 11:20samples, we did some genetic testing.
- 11:22Then what? How did we compare them?
- 11:24So there's really this score that we can use on the genetic
- 11:27testing that ranges from zero to 1.
- 11:30And if the score is a zero, that means those two things are not
- 11:33related at all. And if it gets a one, then that
- 11:36means those things are perfectly related.
- 11:38They're probably like identical to twins, let's say.
- 11:40And so that's what we're going to be looking at is what do
- 11:42those numbers look like? How close does that atypia look
- 11:45to the breast cancer in terms of the genetic changes that we see?
- 11:49So I'm going to give you 2 examples here.
- 11:51So this first patient is a 58 year old and there was about a
- 11:55one year period between the atypia and the invasive cancer
- 11:58that was in the same breast. And these are the genetic
- 12:01analysis. These pictures are mostly here
- 12:03just to look pretty. We don't need to know the
- 12:05details. What matters is the words in
- 12:07pink. You can see that relatedness
- 12:09score. Remember I said zero meant not
- 12:12related, One meant 100% related. And you can see this is pretty
- 12:16close to 1. We're almost at .8, meaning that
- 12:19there was a lot of genetic similarities between the atypia
- 12:22and the breast cancer in this patient.
- 12:25And so specifically we said many of them were, there were some
- 12:28genetic changes that were specific to these patients, but
- 12:31again highly related. So then looking at our next
- 12:35patient that I wanted to share with you, this one is actually
- 12:37on the other end of the spectrum.
- 12:39So this patient also about 60 years old, much longer time
- 12:42frame though between the atypia and the invasive cancer, but
- 12:46again near each other. Again, the pictures are mostly
- 12:48there to look pretty, but look at those pink numbers, remember
- 12:510 not related, one perfectly related.
- 12:54So if we look at the cancer and the atypia in the middle, that
- 12:58related score was much lower for this patient, so about a 40%
- 13:02related. And then interestingly, this
- 13:04patient had some what we call hyperplasia, which means that
- 13:07the cells weren't abnormal looking, but there were more of
- 13:10them than we expected. And that particular area, which
- 13:13was not what we were studying specifically, but was kind of
- 13:16nearby. So we also took a look at it.
- 13:18It was actually more related to the invasive cancer than the
- 13:21area of atypia. So that was kind of an
- 13:23interesting unexpected finding that we're thinking about
- 13:25exploring in future studies as well.
- 13:28So again, they are related, but not quite as related as they
- 13:31were with the other patient that we saw.
- 13:33And again, we had this interesting finding where we saw
- 13:36some relatedness that was rather unexpected.
- 13:39So for this particular study, again, we we've just kind of
- 13:42gotten through all of that analysis.
- 13:44Unfortunately, we lost our lab technician that was doing all of
- 13:48that work. And so we've been on a slight
- 13:49pause while we've been trying to fill that gap.
- 13:52But overall, we've been, we've been able to show that the
- 13:54genetic changes in the utopia and the invasive cancers are
- 13:57genetically related for many patients, which is similar to
- 14:00what this lab, doctor Marks lab had shown with the DCIS.
- 14:04However, interestingly, how similar they are, the atypia and
- 14:08the invasive cancer does not seem to correspond to the
- 14:11timing, meaning it's not like, oh, if it occurs quickly, they
- 14:15were genetically related, but if it took a long time to get
- 14:18breast cancer, they maybe they were less related.
- 14:20So that was kind of an interesting finding.
- 14:22And then as I mentioned, we are still analyzing this data and
- 14:25trying to figure out, you know, if there's some additional
- 14:27things that we could look at that would be useful.
- 14:30And really, to our knowledge, this is the first study that's
- 14:32looked at this correlation between genetic changes in
- 14:35atypia and subsequent breast cancer.
- 14:37So really novel findings. Even though a small study, only
- 14:4012 patients, it's certainly going to be able to add to the
- 14:43literature because there's really nothing else out there
- 14:45like it. So that is the first study that
- 14:47I wanted to share with you. And so I'm now I'm going to
- 14:49spend just a couple minutes going over project #2 and this
- 14:52is one that is also ongoing. And this was looking at
- 14:55improving our understanding of sharing genetic information
- 14:59among patients who have genetic mutations related to breast
- 15:02cancer. And the way we did this study
- 15:04was totally different. So we didn't have any specimens
- 15:07to dissect and do genetic testing on.
- 15:09This was actually talking to patients.
- 15:11So patients who have genetic mutations, meaning things they
- 15:14were born with that maybe put them at risk for developing
- 15:17breast cancer. And we talked to patients in two
- 15:19ways or got information from them rather one was doing
- 15:23surveys, so electronic surveys that sent out and that survey
- 15:26has been completed. And that's the information I'll
- 15:29share with you today. And we are currently in the
- 15:31process of doing one-on-one patient interviews, so actually
- 15:35talking to patients, asking them more detailed questions about
- 15:38why they did or didn't share this information with their
- 15:41families. Because when someone has a
- 15:42genetic mutation, it's very likely that there are other
- 15:46living family members that also have that mutation that may
- 15:48benefit from that knowledge. And so we're trying to really
- 15:51understand why people do or don't share that information
- 15:55with their families so that their family members can also
- 15:57get tested. So again, today we're going to
- 15:59focus on those surveys. So this survey, we actually were
- 16:02able to get responses from about 160 of the patients that we
- 16:06offer the survey to and most of them filled out the entire
- 16:09survey. So we had 154 total responses
- 16:12that we included. The average patient age was
- 16:14around 47 years old. Interestingly, the Raleigh
- 16:18Durham area actually has a high proportion of minorities that
- 16:21could be in like the 20 to 25% range.
- 16:24And that's why I was really hoping that when we did this
- 16:26study at Duke, we would try and get something pretty close to
- 16:29that. We were a little lower than I
- 16:32expected, particularly in terms of the Black and African
- 16:34American population in our area. Only 8% of our respondents
- 16:38identified with that race, which was lower than anticipated, but
- 16:42still helpful. And you can see here, we had
- 16:44about 5% that identified as Hispanic, Latino or Spanish.
- 16:48Most respondents were female, so not surprising there since we're
- 16:51looking at breast cancer susceptibility.
- 16:53Most of them were cisgender females in particular.
- 16:56You can see many of them were married or in domestic
- 16:59partnerships. You can see the household
- 17:01incomes here and a lot of educated participants or
- 17:04respondents as well. So looking at the types of
- 17:07mutations they had, many of these respondents had mutations
- 17:11in BRCA one or two, because again, we're talking about
- 17:13breast cancer or other high penetrance, meaning things that
- 17:16put you at a super high risk for getting breast cancer.
- 17:19Moderate penetrance means it's kind of moderately increases
- 17:22your risk of getting breast cancer.
- 17:24And then the thing we were really wanting to know again is
- 17:26who are they sharing this information with?
- 17:28Are they sharing it with their children?
- 17:30Are they sharing it with their siblings?
- 17:32So obviously as an important part of that is do they have any
- 17:34siblings? It's hard to share it with your
- 17:36brother and sister if you don't have a brother and sister, But
- 17:39you can see here that the majority of people had siblings.
- 17:42So a little under 90% around 8085 have at least one sibling
- 17:47and many of them also had children.
- 17:49So you can see here again, over half of our cohort had at least
- 17:52one child. So they definitely had people
- 17:54that they could share this information with.
- 17:57And so getting into some of these results, we asked first,
- 17:59did you share any of this information with people?
- 18:02So in terms of biological children, you can see that about
- 18:0510% of them did not share these results with their children,
- 18:09which is kind of interesting. Oftentimes people will do
- 18:12things, will not necessarily do things, I mean, for themselves,
- 18:16But when you ask them to do it on behalf of their children,
- 18:19often I'll get a yes. Particularly for mothers.
- 18:21I'm very good at convincing a mom to do something on behalf of
- 18:24their children. Nothing like mom Guild I'm sure.
- 18:27But interestingly, 10% of people here had not shared this
- 18:29information with their children. A similar number had not shared
- 18:32that information with their siblings, meaning their brothers
- 18:35and sisters. So about 10% there.
- 18:37And another 10 to 20% had actually not shared it with both
- 18:40of their parents. Overall, though, I was surprised
- 18:44to see that about a third of them had not shared this
- 18:47information with any other biologic relatives, meaning like
- 18:50aunts, uncles, grandparents, cousins.
- 18:52Because again, if somebody has this mutation, it's something
- 18:55that other people in their family also could have been born
- 18:57with and might benefit from knowing so that they could, you
- 19:01know, undergo advanced screening or preventative surgeries.
- 19:04And so again, really working on that prevention piece of
- 19:06preventing breast cancer or finding it earlier because we're
- 19:09doing more intense screening. So it would be really helpful if
- 19:12these people knew that they needed to do those things.
- 19:15So these are some more specific questions we asked people.
- 19:18So how confident are you that they could get advice about
- 19:20medical topics? How would you describe your
- 19:23knowledge? So you could see here we've got
- 19:25some people that did not feel comfortable really with genetic
- 19:28knowledge, some even about a fourth saying no knowledge at
- 19:30all. And how would you describe your
- 19:33knowledge? After meeting with genetic
- 19:34counselor, you can see we got some significant improvements
- 19:36there that people about over half felt very, extremely
- 19:40knowledgeable. And you know, how confident are
- 19:42you in your ability to understand your genetic test
- 19:44results? Again, very confident.
- 19:46Almost half are fairly confident.
- 19:48Another half, how confident are you in your ability to explain
- 19:50it to others, though probably not quite as high.
- 19:53But again, still 60% said fairly confident and your ability to
- 19:57understand their impact on others.
- 19:59Again, people seem to think they pretty much understood this
- 20:02could affect my family and yet still we're choosing not to
- 20:05share that information. So kind of an interesting
- 20:08economist finding there. How much do you think genetics
- 20:11that you know, these characteristics are passed down
- 20:13from generation determine that a person will develop cancer and
- 20:16see a lot somewhat. So again, really showing their
- 20:19understanding of what they have. How important is it to know
- 20:22that, you know, genetic information for preventing
- 20:24cancer? You can get and see a lot of
- 20:26people agree it's very important or somewhat important yet again,
- 20:29or choosing not to share that information with their family.
- 20:33So how important is knowing a person's genetic information for
- 20:36detecting cancer early? Again, 85% said it's very
- 20:39important, yet still choosing not to share that information
- 20:43with some relatives. So then the last two questions
- 20:46are really focused on, you know, how important were these reasons
- 20:49for why you did share? And then alternatively, for
- 20:51those who didn't share, we asked why didn't you share that
- 20:54information? So for people who chose to share
- 20:56the information, they wanted to give their relatives information
- 21:00about genetic risks. So that was extremely important
- 21:02to many of them. They wanted to encourage their
- 21:04relatives have genetic testing. Again, that was very and
- 21:07extremely important to most. After I encouraged it, that also
- 21:10was a consideration, but for some, not so as important.
- 21:13It was helpful for making family planning decisions for some
- 21:15people, but others not so important, probably likely due
- 21:18to where they're at in their lives.
- 21:19Some have probably already had their families.
- 21:22They wanted to share the information because they thought
- 21:24it was interesting and again, not particularly a reason they
- 21:26thought that they would share. They wanted to share feelings.
- 21:29Again, some importance but not super important.
- 21:33And then they wanted to get help from blood relatives with
- 21:35coordinating and planning. Again, somewhat important, but
- 21:38not really one of the more important factors.
- 21:41So why didn't people share this information?
- 21:43So they found out they have one of these mutations, it's putting
- 21:46them at risk for breast cancer. Why didn't they share that
- 21:49information with family? Well, one of the reasons you can
- 21:52see here we asked them was did you, were you worried you were
- 21:55going to upset them or worried them?
- 21:57Well, some people thought that was important, but many people
- 21:59said, no, that wasn't why I did it.
- 22:02Well, would you have to talk to a blood relative you're not
- 22:05close to or somebody you don't want to talk to?
- 22:06And some people, and most people said, again, that's probably not
- 22:09why I didn't tell them, but some people that was the reason, You
- 22:13know, some people said that they don't have contact with your
- 22:15blood relatives. But again, not super important
- 22:17for many privacy concerns. Again, something some people
- 22:21would be worried about, but not a super big concern.
- 22:24I don't know how to explain the results.
- 22:25Again, that was the one of the lesser common things.
- 22:29I don't think this information is useful, which again, they
- 22:31already told me they thought this information was useful, but
- 22:34some people here said, you know, maybe not useful, which is kind
- 22:37of interesting. And then some people were just
- 22:39having trouble with the results and just probably weren't ready
- 22:41to share that information. And so that came up for some
- 22:44patients as well. This just kind of helped us give
- 22:47us a better understanding of why people may or may not have
- 22:50shared that. And I think now that we're doing
- 22:52some of those deeper dive interviews, we're really going
- 22:54to be able to go zone in a little bit deeper on these
- 22:57responses and why some people said it is important to know
- 23:00this, yet I chose not to share it because there's only so much
- 23:04we can get from a survey as these are kind of limited
- 23:07responses. And I think that by doing these
- 23:09in person interviews, we're going to be able to get a much
- 23:12richer response and understanding of why some people
- 23:14do or don't share this information.
- 23:17So these were some additional questions we're going to go over
- 23:19today. So with regards to genetic
- 23:21counseling, what are the first steps that someone should take
- 23:24and who should seek genetic counseling?
- 23:26Let's pause there. And let us set you up for an
- 23:30additional time frame if that would be good because I really,
- 23:34because now you've given given me a lot of things to think
- 23:37about. And I think it would be great
- 23:40for you to be able to share the rest of that information and
- 23:43then the other questions that we had for you.
- 23:45So if you're willing, we would certainly love to invite you to,
- 23:50to do this again for us. It's so helpful.
- 23:52And, and one of the things I was thinking about with is with DCIS
- 23:58and how difficult that is for people to, to deal with what.
- 24:05So where am I with that? So, so I'll send you some more
- 24:09questions and then we will get you set up for another
- 24:12additional interview. So I really, really appreciate
- 24:16it. Yeah, of course.
- 24:17No, this has been fun. I'm always happy to share our
- 24:19work and let you know where things are.
- 24:21And the progress we're making, it's always slower than you'd
- 24:24want it to be, you know, on my end anyway, progress can never
- 24:28come fast enough, but we are making progress and just excited
- 24:32that we're able to do the work that we're doing.
- 24:34And again, large part and thanks to, you know, great
- 24:37collaborators like yourselves. We really appreciate it and we
- 24:41will get back in touch with you. OK.
- 24:44Thanks a bunch all. Right, Bye, bye.
- 24:48This episode of Isn't That Interesting was made possible
- 24:51thanks to volunteers and donors just like you.
- 24:54It was hosted by Martha Kaley, founderofearlier.org and edited
- 24:58by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 25:02you that for the last 30 years, this is North Carolina based
- 25:05organization has helped fund groundbreaking research all over
- 25:09the world, from molecular imaging to a sensitive blood
- 25:13test for breast cancer. Plain and simple, earlier
- 25:16detection saves lives. And you can help host a
- 25:19fundraising event, make a donation or volunteer your time.
- 25:23You can find us not only on the web, but on Facebook and
- 25:25Instagram too. Let's change the picture of
- 25:28breast cancer together.